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Abstract:  
In the present study, an effort was made to develop the pulsatile drug delivery of Losartan potassium to the colon. A 
time delayed capsule was prepared by sealing the microspheres inside the insoluble hard gelatin capsule body with 
erodible hydrogel plug. The microspheres were prepared by emulsion solvent evaporation technique.. Optimized 
microsphere formulations were selected based on dissolution studies. The entire device was enteric coated, so that 
the variability in gastric emptying time can be overcome and a colon-specific release can be achieved. Hydrogel 
plug (HPMCK100 and lactose in 1:1 ratio) having 4.5kg/cm2 hardness and 100 mg weight was placed in the capsule 
opening and found that it was satisfactory to retard the drug release in small intestinal fluid and to eject out the 
plug in colonic fluid and releasing the microspheres into colonic fluid after a lag time criterion of 5 hours. In order 
to simulate the pH changes along the GI tract, three dissolution media with pH 1.2, 7.4 and 6.8 were sequentially 
used. FTIR study confirmed that there was no interaction between drug and polymer. Among all the formulations 
Losartan potassium micropheres prepared with cellulose acetate in 1:2 ratio shown   prolonged release for a period 
of 12 hours. The obtained results revealed the capability of the system in delaying drug release for a programmable 
period of time and can prevent a sharp increase in the blood pressure during the early morning hours, a time when 
the risk of hypertension   is the greatest. 
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INTRODUCTION:  
Pulsatile systems are designed in a manner that the 
drug is available at the site of action at the right time 
in the right amount. These systems are beneficial for 
drugs having high first-pass effect; drugs 
administered for diseases that follow 
chronopharmacological behavior, drugs having 
specific absorption site in GIT, targeting to colon, 
and cases where night time dosing is required [1]. 
Cardiovascular events occur more frequently in the 
morning, and ambulatory blood pressure (BP) 
exhibits a diurnal variation with increase in the 
morning(morning BP surge). The morning BP surge 
was reported to be associated with high risk of 
cardiac death, and ischemic and hemorrhagic stroke 
[2]. Losartan potassium is the first orally active 
angeotensin II receptor antagonist, losartan is 
extensively metabolized in liver[3]. It is widely 
prescribed in the treatment of hypertension. It 
undergoes extensive biotransformation and has an 
elimination half life of 1.5 – 2hr. It can use for the 
therapy of symptoms or disease that according to 
circadian rhythms and chronobiology become worse 
during night or in early morning. For these cases 
conventional drug delivery system are inappropriate 
for the delivery of drug, as they cannot be 
administrated just before the symptoms are   
worsened because at that time the patients are 
sleeping[4]. Due to its short biological halflife and 
low bioavailability, it requires frequent 
administration. Thus chronopharmaceutical drug 
delivery system will synchronize the drug delivery 
with the circardian variation in periods of increased 
risk which is highly desirable for hypertensive 
patients. The main objective of present work is to 
formulate and evaluate the chronopharmaceutical 
drug delivery system containing losartan potassium 
for the treatment of hypertension which is used to 
deliver the drug at specific time as per 
pathophysiological needs of the disease and 
improvement of therapeutic efficacy and patient 
compliance. 
The pulsatile drug delivery of Losartan potassium can 
be taken before bed time (10 pm) and capable of 
releasing drug at 3.00 am by proportioning drug 
concentration in the early morning hours when free 
cholesterol levels are more prevalent[5]. The  
intentionally delaying the drug absorption for a 
specified time period of 5 hours( lag time) was 
controlled by hydrogel plug which will be taken at 
bed time with a programmed start of drug release 
early in morning hours 
 
MATERIALS AND METHODS: 
Losartan potassium was a gratis sample obtained 
from Ranbaxy Lab. Ltd. (India).Eudragit RLPO and 
Eudragit RSPO were obtained from Himedia; 
Mumbai. HPMC K100, carbapol, Na CMC and 
Methyl Cellulose were purchased from SD fine 
chemicals, Mumbai. All reagents used were of 
analytical-reagent grade. 
 
Preparation of Cross-Linked Gelatin Capsules: 
Approximately 100 number size 0 hard gelatine 
capsules were taken. Bodies were separated from cap, 
25 ml of 15% (v/v) formaldehyde was taken into 
desiccators and a pinch of potassium permanganate 
was added to it, to generate formalin vapours. The 
wire mesh containing the empty bodies of capsule 
was then exposed to formaldehyde vapours. The caps 
were not exposed leaving them water-soluble. The 
desiccators were tightly closed. The reaction was 
carried out for 12 h after which the bodies were 
removed and dried at 500C for 30 min to ensure 
completion of reaction between gelatin and 
formaldehyde vapours. The bodies were then dried at 
room temperature to facilitate removal of residual 
formaldehyde[6]. These capsule bodies were capped 
with untreated caps and stored in a polythene bag. 
Table 1: Preparation of  Losartan potassium microspheres 
 
 
 
 
 
 
 
Polymer employed 
Eudragit RLPO Eudragit RSPO 
Formulation Code Core: Coat Formulation Code Core: Coat 
F-1 1:1 F-4 1:1 
F-2 1:1.5 F-5 1:1.5 
F-3 1:2 F-6 1:2 
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Preparation of Hydrogel Plug: 
Plug for sealing the capsule body was prepared by 
compressing equal amount of equal amount of 
HPMC K100: lactose, carbapol: lactose, Na CMC: 
lactose, and Methyl Cellulose: lactose using 7 mm 
punches and dies on rotary tablet press keeping 
varying thickness and hardness values of tablet 
plug[7] . 
 
Preparation of microspheres: 
All the microspheres formulations were prepared by 
emulsion solvent evaporation technique [8]  and the 
composition was shown in table 1. The effect of 
various formulation and processing factors on 
microspheres characteristics were investigated by 
changing polymer: drug ratio. Weighed amount of 
Losartan potassium and polymer in 1:1 ratio were 
dissolved in 10ml of chloroform. The homogeneous 
drug and polymer organic solution was then slowly 
added in a thin stream to 100ml of liquid paraffin 
containing 1% surfactant (span 80) with constant 
stirring for 1h. The resulting microspheres were 
separated by filtration and washed with petroleum 
ether. The microspheres finally air dried over a 
period of 12 hrs and stored in a desiccator. In case of 
1:1.5and 1:2 core:coat ratios, the corresponding 
polymer get varied respectively. 
 
Designing of Pulsincap: 
The Pulsincap was designed   by filling the 
microspheres equivalent to 50mg of Losartan 
potassium into the formaldehyde treated bodies by 
hand filling. The capsules containing the 
microspheres were then plugged with optimized 
hydrogel plug. The joint of the capsule body and cap 
was sealed with a small amount of the 5% ethyl 
cellulose ethanolic solution[9]. The sealed capsules 
were completely coated by dip coating method with 
5% cellulose acetate pthalate in 5:5 (v/v) mixture of 
acetone: ethanol plasticized with n-dibutylphthalate 
(0.75%), to prevent variable gastric emptying. 
Coating was repeated until an 8–12% increase in 
weight is obtained. % weight gain of the capsules 
before and after coating was determined[10]. 
 
Physicochemical Characterization of Hydrogel 
Plug 
Hydrogel Plugs were studied for hardness, friability, 
weight variation and lag time[10]. 
 
Drug content uniformity: 
Then encapsulated microspheres equivalent to 50mg 
of Losartan potassium were taken into mortar and 
grounded with the help of pestle.  The grounded 
power mixture was dissolved in 6.8 pH buffer , 
filtered and estimated spectrophotometrically at 285 
nm[11]. 
 
In vitro release profile of pulsatile capsule:   
Drug release studies of pulsincaps were carried out 
using a USP XXIII dissolution rate test apparatus 
(Apparatus 2, 100 rpm, 37 °C) for 2 hr in 0.1 M HCl 
(900 ml) as the average gastric emptying time is 
about 2 hr. Then the dissolution medium was 
replaced with pH-7.4 phosphate buffer (900 ml) for 
3hr as the average small intestinal transit time is 
about 3 hr. After 5 hr, the dissolution medium was 
replaced with pH 6.8 phosphate buffer (900 ml) and 
tested for subsequent hours. Nine hundred milliliters 
of the dissolution medium was used at each time. 
Rotation speed was 100 rpm and temperature was 
maintained at 37±0.5oC. Five milliliters of dissolution 
media was withdrawn at predetermined time intervals 
and fresh dissolution media was replaced. The 
withdrawn samples were analyzed at 285 nm, by UV 
absorption spectroscopy and the cumulative 
percentage release was calculated over the sampling 
times [12]. 
 
Drug excipient compatability studies: 
The IR Spectra for the formulation, pure drugs and 
excipients were recorded on JASCO FT-Infra Red 
Spectrophotometer using KBr pellet technique[13] at 
the resolution rate of 4 cm-1. Spectrum was integrated 
in transmittance mode at the wave number range 380 
to 4368 cm-1  . 
 
RESULTS AND DISCUSSION: 
Pulsincap dosage form was a capsule which consists 
of a water insoluble body and a water soluble cap. 
The microspheres were sealed within the capsule 
body by means of a hydrogel plug. When the pulsing 
cap was swallowed, the water soluble cap dissolves 
in the gastric juice and the exposed hydrogel plug 
begins to swell. At predetermined time after 
ingestion, the swollen plug was ejected out and the 
encapsulated drug formulation was then released into 
the colon, where it is dissolved and then absorbed 
into blood stream. In the present study, capsule 
bodies which were hardened with formaldehyde 
treatment for 12 hrs were used for the preparation of 
pulsincaps. It was sealed with unhardened cap of the 
capsule. The microspheres were prepared by 
emulsion solvent evaporation technique .The method 
employed gave discrete, spherical, non-sticky and 
free flowing microspheres. As aggregates these 
microspheres were also non-sticky and free flowing. 
The formation of a stable emulsion in the early stages 
is important if discrete microspheres are to be 
isolated. An optimal concentration of emulsifier is 
required to produce the finest stable dispersion. 
Below optimal concentration the dispersed 
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globules/droplets tend to fuse and produce larger 
globules because of insufficient lowering in 
interfacial tension, while above the optimal 
concentration no significant decrease in particle size 
is observed, because a high amount of emulsifying 
agent   increases the viscosity of the dispersion 
medium. The optimal concentration of surfactant   
was found to be 1.0%. Microscopic examination of 
the formulations revealed that the microspheres were 
spherical and appeared as aggregates or discrete 
particles. 
All the formulations offered good flow properties. 
The particle size of the microspheres ranged between 
613.23and 662.53μm. The use of the surfactant 
permits the remarkable reduction in the size of the 
microspheres as the result of decrease in the 
interfacial tension. All formulations had a narrow 
particle size distribution. The mean particle size of 
microspheres was influenced by the type of polymer 
proportion in the formulation. The mean size 
increased with increasing polymer concentration. It 
would appear that increasing polymer concentration 
produced a significant increase in viscosity of the 
internal phase, thus leading to an increase of 
emulsion droplet size and finally a higher 
microspheres size. Microspheres were developed 
with 1:1, 1:1.5, 1:2, ratios of core: coat to determine 
the affect of coating material concentration on the 
release rate of  Losartan potassium. These 
microspheres were characterized for Drug Content 
and % Encapsulation Efficiency. The results are 
given in Table 2. The technique also showed good 
entrapment efficiency. Hydrogel Plugs were 
evaluated for hardness, friability, weight variation 
and lag time and the results were shown in Table 3. 
The formulations  fitted with the various  hydrogel 
plugs  HP1,HP2, HP3, HP4  shown  0.4% , 7.14% , 
15.63 % and 18.21 %  of drug  release respectively at 
the end of 5th hour . It was observed that 100 mg 
hydrogel plug (HPMC K100: lactose in 1:1 ratio) 
having 4.5kg/cm2 hardness was satisfactory to retard 
the drug release in small intestinal fluid and to eject 
out the plug in colonic fluid and releasing the 
microspheres   into colonic fluid. This suggested that 
the lag time could also be adjusted   and influenced 
by the plug composition. 
During dissolution studies, it was observed that, the 
enteric coat of the cellulose acetate phthalate was 
intact for 2 hrs in pH 1.2, but dissolved in intestinal 
pH, leaving the soluble cap of capsule, which also 
dissolved in pH 7.4, then the exposed polymer plug 
absorbed the surrounding fluid, swelled and released 
the drug through the swollen microspheres. After 
complete wetting of the plug, it formed a soft mass, 
which was then easily ejected out of the capsule 
body; releasing the microspheres into simulated 
colonic fluid (pH 6.8 phosphate buffer). From the In-
vitro release studies of device, it was observed that 
with all formulation, there was absolutely no drug 
release in simulated gastric fluid (acidic pH 1.2) for 2 
hours and in simulated intestinal fluid (pH 7.4 
phosphate buffer). Burst effect was found in colonic 
medium (pH 6.8 phosphate buffer). 
In-vitro release profiles in colonic medium were 
found to have very good sustaining efficacy. Pulsin 
caps  loaded with  Losartan potassium microspheres   
prepared with Eudragit RLPO  in 1:1,1:1.5 and 1:2  
ratios  shown sustained drug release for  a period  of  
10 hours (5th hour to 15th  hour), 11 hours ( 5th hour to 
16th hour)  and 12 hours( 5th hour to 17 hour) 
respectively. respectively and are shown in figure 
1.Pulsin caps  loaded with  Losartan potassium 
microspheres   prepared with Eudragit RSPO in 
1:1,1:1.5 and 1:2  ratios  shown sustained drug 
release for  a period  of  9.5 hours (5th hour to 14.5th  
hour), 10.5 hours ( 5th hour to 15.5th hour)  and 11.5 
hours( 5th hour to 16.5 hour) respectively  and are 
shown in figure 2.   
 
Table 2: Evaluationl data of Losartan potassium microspheres 
 
Formulation Angle of  Repose 
Bulk 
Density 
( g/cm3) 
Tapped 
density 
(gm/cm3
) 
Carr’s 
Index 
Hausner’s 
Ratio 
Average 
 Particle 
Size (µm) 
% Drug 
 Content 
% 
Encapsul
ation 
Efficiency 
F-1 26.52 0.522 0.619 15.67 1.185 561.28 48.23 96.46 
F-2 26.14 0.524 0.620 15.48 1.183 579.16 39.11 97.77 
F-3 25.73 0.527 0.622 15.27 1.180 588.24 32. 62 97.95 
F-4 27.64 0.514 0.611 15.87 1.188 522.17 48.56 97.12 
F-5 26.93 0.519 0.614 15.49 1.183 548.28 39.29 98.22 
F-6 26.10 0.521 0.616 15.42 1.182 568.19 32. 41 98.21 
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Table: 3 Evaluation characteristics of hydrogel plugs prepared with various natural polymers 
 
Hydrogel Plug 
 Code  
 
Composition 
(1:1) 
Weight 
(mg) 
Thickness 
(mm) 
 
Hardness 
(kg/cm2) 
 
Lag time 
(hours) 
 
HP1 HPMC K 100 : 
Lactose 
100±1.4 3.16 4.7 5 
HP2 Carbopol : Lactose 100±1.1 3.29 4.2 4.5 
HP3 Na CMC : Lactose 100±1.5 3.24 3.8 4 
HP4 Methyl Cellulose : 
Lactose 
100±1.2 3.54 3.5 3 
 
Table: 4 In-vitro disssolution kinetics parameters of Losartan potassium microspheres 
 
 
Formulation 
 
          Correlation  coefficient 
        
        Release kinetics 
Diffusion 
Exponent 
value(n) Zero 
order 
First 
order 
Higuchi Peppas K o 
(mg/hr) 
T50 
   (hr) 
T90 
   (hr) 
           F1 0.9990 0.6859 0.9271 0.9968        4.90 5.1 9.1 0.8732 
           F2 0.9983 0.8085 0.9352 0.9983 4.54 5.5 9.9 0.8651 
           F3 0.9965 0.7450 0.9355 0.9989 4.16 6 10.8 0.8594 
           F4 0.9907 0.8211 0.9561 0.9956 6.41 3.9 7.0 0.7385 
           F5 0.9895 0.8206 0.9573 0.9971 5.81 4.3 7.7 0.7508 
           F6 0.9925 0.8353 0.9506 0.9964 5.07 4.93 8.88 0.7643 
 
 
 
Fig 1: Comparative In-vitro drug release profiles plot of Losartan potassium microspheres prepared with 
Eudragit RLPO in different ratios 
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Fig 2: Comparative In-vitro drug release profiles plot of Losartan potassium microspheres prepared with 
Eudragit RSPO in different ratios 
 
Fig 3: FTIR spectrum of pure Losartan potassium 
 
 
Fig 4: FTIR spectrum of optimized formulation 
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The correlation coefficient values for dissolution 
kinetics data was shown in the Table 4. These values 
clearly indicated that the drug release followed zero 
order kinetics and the   mechanism of drug release was 
governed by 
peppas - korsmeyer model. The exponential coefficient 
(n) values were found to be in between 0.7551 to 0.9730 
indicating non fickian diffusion mechanisam. 
The FTIR spectrum of Losartan potassium pure drug 
(Figure 3) appeared at 
3038.22,3399.52,1130.98,1642.23,1356.36,1571.12 and 
2926.99 denoting stretching vibration of C-H-,N-H-,O-
H-,C=N,C-N,N=N and aromatic ring, respectively. The 
FTIR spectrum (Figure 4) of optimized formulation (F4) 
showed the same peaks. There were no change or 
shifting of the characteristic peaks in drug and excipient 
mixtures suggested that there was no significant drug 
polymer interaction which indicates the stable nature of 
the drug in all formulations. From the figures it was 
observed that similar peaks were also reported in 
optimized formulation. There was no change or shifting 
of characteristic peaks in drug loaded microspheres   
suggested that there was no significant drug polymer 
interaction which indicates the stable nature of the drug 
in optimized formulation.  
 
CONCLUSION:  
Among all the formulations Pulsin caps loaded with 
Losartan potassium microspheres   prepared with 
Eudragit RSPO in 1:2 ratio shown prolonged release for 
a period of 12 hours. The obtained results showed the 
capability of the system in delaying drug release for a 
programmable period of time and the possibility of 
exploiting such delay to attain colon targeting. In 
accordance with the chronomodulated therapy of 
hypertension, the lag time criterion of 5 hours and 
sustained release for a period of 12 hours was satisfied. 
The dosage form can be taken at bed time and will 
release the contents in the early morning hours when 
hypertension is more prevalent. 
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